



Department of Health
and Community Services

Winter 2006

Behind the Scenes

Newfoundland and Labrador Prescription Drug Program (NLPDP)

Prescribing of Cholinesterase Inhibitors CME Update

Planning is currently underway for the Department of Health and Community Services to provide a Prescribing of Cholinesterase Inhibitors CME through a web-based format. It is expected that this will be available in early 2007.

Designated Prescriber status continues to be available upon completion of the Request for Designated Prescriber Status form listing previous training in the diagnosis and treatment of Dementia. This form as well as those for requesting coverage of Cholinesterase Inhibitors are available through the NLPDP office (709-729-6507 or 1-888-222-0533 or fax 709-729-2851), and on the NLPDP web site at http://www.health.gov.nl.ca/health/nlpdp/cholinesterase_inhibitors.htm

Physician Special Authorization Notification

Physicians can now receive notification of special authorization approvals by fax. Avoid delay by postal service and receive notification the same day as pharmacies. Contact NLPDP at **753-3615** or **1-888-724-7760** for a form to request the change from mail to fax notification.

CHANGES TO THE NLPDP BENEFIT LISTING

New open benefits:

Tri-Cyclen Lo Tab (21 day)	Income Support Program only
Tri-Cyclen Lo Tab (28 day)	Income Support Program only
Eligard 45mg	Income Support and Senior Citizens Programs
Apo-Methylphenidate 5mg	Income Support and Senior Citizens Programs
PMS- Citalopram 5mg	Income Support and Senior Citizens Programs
Migranal 4mg/ml Nasal Spray	Income Support and Senior Citizens Programs

Special Authorization

Coverage criteria can be viewed at <http://www.health.gov.nl.ca/health/nlpdp/>

The following medications are now being considered under Special Authorization:

Avandmet	Uromax CR 10mg and 15mg
Venofer	Prevacid 30mg Fas Tabs
Oxycontin 5mg	Enbrel 50mg/mL
Twinject 0.15mg and 0.3mg	Avonex PS

The following special authorization medications have new coverage criteria:

Proscar 5mg
Diovan 80mg and 160mg
Zanaflex 4mg

The Newfoundland and Labrador Interchangeable Formulary

New Categories Effective January 1, 2007:

Azithromycin Powder for Oral Suspension 100mg/5ml and 200mg/5ml
Betahistine Dihydrochloride 16mg and 24mg Tablets
Famciclovir 125mg, 250mg and 500mg Tablets
Fenofibrate 100mg and 160mg Tablets
Fentanyl Transdermal System 25mcg, 50mcg, 75mcg and 100mcg Patches
Midodrine Hydrochloride 2.5mg and 5mg Tablets
Mirtazapine 15mg, 30mg and 45mg RD Tablets
Ondansetron 4mg and 8mg Tablets
Oxcarbazepine 150mg, 300mg and 600mg Tablets
Risperidone 0.25mg, 0.5mg, 1mg, 2mg, 3mg and 4mg Tablets
Risperidone 1mg/ml Solution
Tamsulosin Hydrochloride 0.4mg Capsules SR
Oxycodone HCL/Acetylsalicylic Acid 5/325mg Tablets

Drug Reviews Completed and Not Considered for Coverage

The Atlantic Common Drug Review (ACDR) is a regional review process that provides evidence-based recommendations for coverage of new indications and line extensions for existing medications. Drug evaluation summaries are prepared by independent reviewers based on the manufacturer's drug submission and a systematic literature search. The drug evaluation summary is presented to the Atlantic Expert Advisory Committee who recommends the place in therapy. It is then up to each individual province to make a decision as to the coverage status. A review for the following product was completed by the ACDR and coverage was not recommended. As such, these products will not be considered for coverage under the NLPDP.

Prav ASA	Atacand 4mg
Niaspan	Xatrol
Lipidil EZ	PhosLo
Diovan 40mg	Zyprexa IM
Aranesp for Solid Tumor	Nutropin for Adult Growth Hormone Deficiency
Botox for Axillary Hyperhidrosis	